Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir

China Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir, Find details about China Darunavir, Darunavir Ethanolate from Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir

Model NO.
Condavo-Darunavir
Name
Darunavir
Product Name
Darunavir Powder
Appearance
White Powder
Test Method
HPLC UV
Storage
Cool Dry Place
Assay
99%
Grade
Pharmaceutical Grade
COA
Available
Mf
C27h37n3o7s
CAS
206361-99-1
Psa
148.80000
Logp
4.42820
Density
1.34G/Cm3
Flash Point
74-76c
Refractive Index
1.62
Trademark
Condavo
Transport Package
1kg/ Aluminium Bag or 25kg/Drum; as Required
Specification
99%
Origin
Shaanxi
Model NO.
Condavo-Darunavir
Name
Darunavir
Product Name
Darunavir Powder
Appearance
White Powder
Test Method
HPLC UV
Storage
Cool Dry Place
Assay
99%
Grade
Pharmaceutical Grade
COA
Available
Mf
C27h37n3o7s
CAS
206361-99-1
Psa
148.80000
Logp
4.42820
Density
1.34G/Cm3
Flash Point
74-76c
Refractive Index
1.62
Trademark
Condavo
Transport Package
1kg/ Aluminium Bag or 25kg/Drum; as Required
Specification
99%
Origin
Shaanxi
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
 
Product Description
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade DarunavirDarunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
Product nameDarunavir
Appearancewhite powder
Assay99%
CAS206361-99-1
Shelf Life24 months when properly stored
StorageCool Dry Place
Darunavir is the latest weapon in the arsenal of agents to combat human immunodeficiency virus type 1(HIV-1).
As an HIV-1 protease inhibitor, its mechanism of action involves blocking the cleavage of the gag and gag-pol polyproteins into functional proteins essential for the production of infectious progeny virus;
Sample Display
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade DarunavirDarunavir Ethanolate Darunavir Material Pharmaceutical Grade DarunavirDarunavir exhibits less than a 10-fold decrease in susceptibility in cell culture against 90% of 3309 clinical isolatesresistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir.In contrast, darunavir-resistant viruses display limited susceptibility to only tipranavir, suggesting limited cross-resistance between these two protease inhibitors.To avoid the issues of the peptide-based protease inhibitors, darunavir has evolved from a structure-based design effort to minimize peptidic features and reduce molecular weight and complexity.Darunavir Ethanolate Darunavir Material Pharmaceutical Grade DarunavirTreatment of HIV infection (in combination with other antiretroviral drugs)Darunavir is less affected than other protease inhibitors by mutations to resistance, but subgroups with more than 10 cumulative mutations show a >10-fold (median value) decrease in susceptibility. The major resistance mutations occur at positions 50 (150V), 54 (I50M/L), 76 (L76V) and 84 (I84V) of the protease gene.
Specification
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade DarunavirDarunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
Packaging & Shipping
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
Certifications
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
Our Team
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir
About Us
Darunavir Ethanolate Darunavir Material Pharmaceutical Grade Darunavir